Elevated levels of serum lipoprotein(a) [Lp(a)] are reported to be associated with risk of atherosclerosis and thrombosis. Little is known about the influence of Lp(a) on the progression of coronary artery disease. We evaluated the association of serum Lp(a) and the longterm changes of angiographic severity in patients who underwent repeated coronary angiography at intervals of more than 2 years. We evaluated 70 patients, and divided them into 3 groups by angiographic findings. Median Lp(a) concentration was significantly higher in the progression group (N = 36) than in the no-change group (N = 23) or the regression group (N =11) (32.4 vs 22, 19.3 mg/dl, p < 0.05). Furthermore, the progression group had more patients whose Lp(a) levels were greater than 30 mg/dl (p = 0.006), while in the regression group all patients were under 30 mg/dl. Stepwise logistic regression analysis for progression of lesions showed that Lp(a) 30 mg/dl remainedsignificant, giving an estimated odds ratio (OR) of 2.46 (p = 0.005). In the subgroup analysis, OR in patients with mild lesions was reduced to 2.05 (p < 0.05) while in patients with severe lesions OR was increased to 3.39 (p = 0.003). The serum Lp(a) level has a close correlation with angiographic progression, and may be an important predictor for progression.
Introduction
Lipoprotein(a) (Lp(a)) is a complex lipoprotein, it was first described by Berg in 1963 (1) as being composed of a lowdensity lipoprotein(LDL) particle linked by a disulfide bridge from apoB-100 to a unique apolipoprotein, apo(a) (2, 3). In the 1970s, some investigators reported an association between Lp(a) and coronary artery disease(CAD). The recent determination of the amino acid sequenceand subsequently the cDNA sequence of apo(a) provided new insights in the potential mechanistic relevance of Lp(a). Apo(a) has a striking homology to the fibrinolytic proenzyme plasminogen (4). Since the structural and functional properties of Lp(a) were discovered, it has attracted much attention from many investigators as an independent risk factor for atherothrombotic diseases (5).Elevated levels of serum Lp(a) are associated with an increased risk of atherosclerosis and its manifestations, such as CAD, stroke, and the restenosis after percutaneous transluminal coronary angioplasty (PTCA), especially when the level is more than 30 mg/dl (6-10). Lp(a) has also been suggested to promote atherothrombosis and thereby increase the risk for acute myocardial infarction. These associations are supported by its structural similarity to plasminogen and by in vitro evidence for interference with the physiologic functions of plasminogen (11-13).
Previous coronary angiographic studies have shown that Lp(a) levels are correlated with the extent and severity of coronary atheroscrelosis.
Lp(a) levels are also a predictor of recurrent acute myocardial infarction andrapid angiographic progression, and progression of atherosclerosis in a saphenous vein graft after coronary artery bypass surgery (14, 15). However the role of Lp(a) in coronary atherosclerosis progression remains controversial. The aim of this study was to evaluate the association of serum lipid especially Lp(a) and the long-term changes of angiographic severity in patients who underwent repeated CAG at intervals of more than 2 years.
Methods

Subjects
This is a retrospective study that investigated the relation between Lp(a) levels and angiographic progression in patients who underwent two sequential coronary angiograms. From the cardiac catheterization laboratory data base of Juntendo University Hospital, patients meeting to the following criteria were included. 1) sequential angiograms greater than 2 years apart, 2) Lp(a) levels measured at least once during the study period. Patients who had undergone coronary artery bypass surgery and/ or percutaneous transluminal coronary angioplasty were excluded.
Patients using lipid-lowering drugs known to affect Lp(a) concentrations (e.g., nicotinic acid or its congeners) (16, 17) and patients with acute or recent (less than 1 month after the onset) myocardial infarction were also excluded because plasma Lp(a) has been reported to increase transitorily in the acute and subacute phases of myocardial infarction (20).
Metabolic variable
Blood samples were collected at the time of arteriotomy before systemic heparinization for the cardiac catheterization after at least 12-hour fasting and were allowed to clot at room temperature for 1 to 2 hours. All sera were obtained under conditions in which proteolysis minimized with EDTA, NaN3, and protease inhibitor and were maintained at 4°C until the assay.
Serum total cholesterol (TC), triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) levels were measured in the clinical chemistry department using standard enzymatic methods.
Serum Lp(a) concentrations were measured as the total lipoprotein mass according to the ELISA method (19) or the latex immunoassay method (Sanwa Co) (20). These two assays correlated well with each other, with the correlation coefficient r = 0.996 and the linear regression of y= 1.04x + 0.05, where x indicates the latex immunoassay method and y indicates the ELISA method (20). The frequency distribution of serum Lp(a) concentrations in healthy Japanese subjects was highly skewed, with a median of 10 to 15 mg/dl (20, 21) which is not significantly different from the results for white populations (21). As the 90th percentile of Lp(a) concentrations in healthy Japanese populations is less than 30 mg/dl (21) and many previous reports have suggested that Lp(a) confers with its pathological effect at the level of more than 30 mg/dl (5, 22), we defined subjects with Lp(a) of 30 mg/dl as having elevated Lp(a). The crude values of LDL cholesterol (LDL-C) were calculated with the use of Friedewald's formula (23).
Clinical characteristics of all patients data were obtained from medical records regarding current smoking habits, presence of diabetes mellitus or hypertension and use of the lipid-lowering drugs.
Coronary angiography
Selective coronary angiography was performed via the right radial artery or the femoral artery by the standard method in the patients.
Isosorbide dinitrate (2 mg) was injected selectively in the right and left coronary ostia before imaging. At least 6 standard projections were obtained and, if necessary, additional angulations were supplemented to achieve optimal visualization of all the segments.
The films were evaluated by two experienced angiographers who were blinded to the patients' risk profiles. The coronary stenosis score was calculated by the modified Gensini's scoring system (24). Briefly, the lumen diameter reduction of each surgical segments or branch of the coronary arteries was given a score between 1 and 32 points according to a luminal narrowing of 25% to 49% (1 point), 50%-74% (2 points), 75-89% (4 points), 90-98% (8 points), 99% (16 points), or total occlusion (32 points). Points were added to a maximum of 96 points per patients.
Patients were categorized into three groups "progression", "regression", and "no-change". Progression was defined as a increase of the coronary artery stenosis score from the first coronary angiogram to the second angiogram, regression as decrease of stenosis score, and no-change as stenosis score unchanged.
For the multivariate analysis we divided the patients into two groups, progression and non-progression, comprising "regression" and "no-change".
In the progression group including the varieties of cases that the underlying lesions were normal to 99% stenosis.
To estimate the severity of underlying lesions, the progression group was divided into two groups ; mild lesion and severe lesion. Mild lesion was defined as a lesion of normal to 49% stenosis, and severe lesion was defined as a lesion of 50% to 99% stenosis. (25)
Statistical Analysis
We used Pearson's chi-squared statistic to compare differences in risk factor prevalence and one way ANOVA to compare continuous variables among the 3 groups, except for the concentration of Lp(a). As the distribution of Lp(a) was highly skewed, the data were summarized as median and 25th and 75th percentiles, and differences of Lp(a) concentrations were evaluated through nonparametric statistical procedures (Mann-Whitney's and Kruskal-Wallis' tests). The lipid levels comparing baseline with follow up were analyzed by a paired t-test.
All probability values for statistical significance were twotailed. The proportion of number of arteries and vascular outcome were analyzed using the chi-squared method.
The multivariate adjusted odds ratio for the progression was estimated with the stepwise logistic regression method, in which age, interval between the sequential angiograms (months), TC,TG, HDL-C at the initial angiogram and at the second angiogram and Lp(a)( __30 mg/dl) were included confounding variables.
As a measure of association between elevated Lp(a) levels (__30 mg/dl) and progression, the Chi-squared test was used. All analyses were performed with the Statistical Package for the Social Sciences (SPSS, SPSS Inc. Chicago, Ilin).
Results
Clinical characteristics
Between 1985 and 1994, 7,390 consecutive cases were stored in the Cardiac Catheterization database, Juntendo University Hospital. Among those, Lp(a) was measured in 2,534 cases.
We found 372 patients who underwent sequential coronary angiographies at least 2 years apart. Two hundred and twenty patients who had had CABG and/or PTCA, 54 patients who had acute coronary syndrome and 28 patients taking niceritrol were excluded. Thus finally, a total of 70 patients meeting the study criteria were identified. Table 1 lists the clinical characteristics of the 70 patients, comprising 65 men (62.4+8.5 y.o.) and 5 women (60.2+9.1 y.o.). Based on the results of the 2 sequential angiographic examinations, we divided the 70 patients into 3 groups, progression group (N=36), no change group (N=23), and regression group (N=11). The mean interval between angiograms was 61+26 months in the progression group, 51+32 months in the no-change group, and 52+21 months in the regression group. There were no significant differences in age among the groups. The systolic (SBP), diastolic (DBP) blood pressure, body mass index (BMI) , prevalence of current smokers (SM), the proportion of patients with diabetes mellitus (DM), fasting blood sugar (FBS) and HbA1c were similar among the groups. The numbers of diseased vessels and Gensini's score at the first angiography among the groups were also not significantly different.
Metabolic variables
Metabolic data of the three groups are listed in Table 2 . Among the groups, TC levels at the baseline did not differ. However, at the second angiogram, the TC levels tended to be lower in the regression group than in the progression or no-change groups (p =0.07). Serum TC levels decreased from the baseline to the second angiogram in each groups (p <0.001 for progression group, p = 0.08 for no change group, p <0.05 for regression group). Delta TC levels (subtraction follow up levels from baseline levels) and the percentage of TC changes (data not shown) did not differ among the groups. At the baseline and the second angiogram, the TG levels tended to be lower in the regression group than in the other groups (p = 0.06, 0.09). HDL-C levels were significantly lower in the progression group than the regression or no-change groups at the baseline (p =0.01) and at the follow up (p = 0.003).
The levels of LDL-C showed similar trends to the levels of TC. LDL-C levels at the baseline did not different among the groups, however at the second angiogram, those in the regression group tended to be lower than the progression or no-change groups ()=0.07). Median Lp(a) concentration was significantly higher in the progression group than in the no-change group or in the regression group (32.4 vs 22 or 19.3 mg/dl, p <0.05).
If the patients were classified into high or normal Lp(a) group by Lp(a) greater than or equal to 30 mg/dl or Lp(a) levels less than 30 mg/dl, the proportion of regression, no-change or progression was significantly different between the two groups (p = 0.006). Half of the progression group had high Lp(a) levels, but all patients in the regression group showed the Lp(a) levels under 30 mg/dl (Table 3) . Table 4 shows the results of the stepwise logistic regression analysis for the predictor of the progression or non-progression of patients. After adjusting for age, interval (month), LDL-C, TG and HDL-C at baseline and at the second angiogram, high Lp(a) level ( 30 mg/di) remained as a significant predictor for the progression of coronary stenosis, with the estimated odds ratio : 2.46 (95% Cl ; 1.32-4.57). The HDL-C level at the second angiogram was also a significant contributor with the odds ratio : 0.89 (95% Cl ; 0.82-0.96).
Multivariate analysis
LDL-C did not remain as a significant predictor. In order to investigate the interaction between the effect of Lp(a) on progression and lesion severity or LDL-C levels, multiple logistic analysis was also performed in the subgroup divided by lesion severity or LDL-C levels at baseline.
Mild lesion was defined as a lesion of normal to 49% stenosis, and severe lesions defined as a lesion of 50% to 99% stenosis (25) . In the mild lesions, high Lp(a) level remained as a significant variable, however the odds ratio was reduced to 2.05 (95% CI ; 1.09-3.84). In patients with severe lesions the odds ratio was increased to 3.39 (95% CI ; 1.53-7.51). The odds ratio of Lp(a) for progression was 1.04 (95% CI ; 1.01-1.09) for patients with LDL-C>130 mg/ dl, and 4.33 (95% CI ; 1.54-12.16) for patients with LDL-C__=130 mg/dl.
Discussion
The results of the present study demonstrated that an elevated Lp(a) level as well as low HDL-C level are significant predictors for angiographic progression of coronary artery stenosis.
The Lp(a) levels in the progression group were significantly higher than those in the nochange group or in the progression group in our study (32.4 mg/dl, 22.0, 19.3 ; p= 0.02). Multiple logistic regression analysis indicated that Lp(a) was an independent predictor for progression, with the odds ratio 2.46 (95% CI ; 1.32-4.57).
Many cross-sectional studies and case-control studies using angiographic or epidemiological methodology have investigated the association of Lp(a) levels with coronary artery atherosclerosis.
They found positive associations between elevated Lp(a) levels and the prevalence and severity of coronary artery disease.
More recently, some prospective studies have demonstrated an association between Lp(a) levels and the development of future coronary events.
Desmarais et al. assessed clinical recurrence after angioplasty and Lp(a) levels in 240 consecutive patients and found a significant association between Lp(a) levels and clinical recurrence after PTCA (26). A rapid progression of coronary atherosclerosis in patients with high Lp(a) levels has been also demonstrated. Terres et al. examined two sequential angiograms taken 66 days apart for angiographic progression in relation to risk factors in 79 prospective patients who were to undergo PTCA (27). They found that Lp(a) levels were significantly higher in those patients with rapid progression. The results of the present study further support the importance of Lp(a) levels in patients with known coronary disease.
After the multiple adjustment of confounding factors, Lp(a) still remained as an independent contributor for angiographic progression.
There remains some controversy regarding the role of Lp(a) in coronary artery disease because some large prospective studies and angiographic studies found no association between the occurrence of cardiac events and the Lp(a) levels. A physician's Health Study, in which 14,916 healthy male physicians were prospectively evaluated, compared Lp(a) levels in 296 men with myocardial infarction and 267 matched controls and found no evidence of association between Lp(a) levels and risk of future myocardial infarction (28). Marburger et al . could not demonstrated the predictive value of Lp(a) for coronary artery atherosclerosis progression in their angiographic regression study (29) . In the present study , patients with LDL-C greater than 130 mg/dl, Lp(a) showed no predictor for progression.
On the other hand Lp(a) was a strong predictor for progression in patients with LDL-C less than 130 mg/dl, indicateing that the role of Lp(a) is especially important in the normocholesterolemic population . This finding was in contrast to the results of the Familial Atherosclerosis Treatment Study, in which Maher et al . demonstrated a correlation of elevated Lp(a) levels and coronary atherosclerosis progression and event rate in the post hoc analysis.
However, once LDL-C is controlled, there may be no predictive value of Lp(a) regarding clinical adverse effects (30) . This descrepancy may be explained by differences in the levels of LDL-C and/or different ethnicity. Further investigation is warranted to resolve this issue.
We observed a slightly higher odds ratio of Lp(a) for progression in patients with severe lesiosn compared with those with mild lesions. This phenomenon was consistent with the findings from previous angiographic trials including the Familial Atherosclerosis Treatment Study in which lesions with higher severity were more prone to progress than mild lesions (31) .
The possible pathophysiological link between elevated levels of Lp(a) and progression of coronary artery disease may be explained by the atherogenic and/or inhibitory effect of Lp(a) on fibrinolysis. Lp(a) accumulates in the atherosclerotic plaques, stimulates smooth muscle proliferation, binds apoB-containing lipoproteion, avidly binds to arterial proteoglycans and fiblinonectin, and promotes cholesterol accumulation on cells (32) . It also promotes thrombosis because of its structural similarity with plasminogen, binds fibrin, and exhibits antifiblinolytic action in vivo (4, 33, 34). With inhibition of fibrinolysis, intravascular thrombus formation may be enhanced in both the presence and absence of a ruptured plaque (35) .
The other factor related to the progression in the present study was a low HDL-C level. HDL-C has an anti-atherogenic effect which is integral to the retrieval of cholesterol from cells and tissues, and low HDL-C levels are associated with an increased risk of coronary artery disease.
Previous angiographic studies have demonstrated its important role against coronary artery atherosclerosis progression.
LDL-C, which is also an important atherogenic lipoprotein, did not remain as a significant predictor for progression.
The levels of LDL-C in the study population might be rather homogeneous and their change in LDL-C might have be an insufficient in the present study.
Limitations
Due to the retrospective nature of the present study, the study population was limited to those who were referred for repeat coronary angiography for miscellaneous reasons without the exclusion criterias.
However, the way in which the patients were selected would not be expected to create a spurious association between level of Lp(a) and coronary artery stenosis progression.
We did not use quantitative coronary angiography (QCA) in the present study because the retrospective analysis of repeat coronary angiograms by QCA might present technical difficulties in frame selections and segment identification of the paired films. Further prospective studies using QCA are warranted.
Conclusions
We conclude that high serum Lp(a) levels and low HDL-C levels have close correlation with angiographic progression of coronary artery disease.
Prospective studies using a larger sample size will be required to confirm these results. 
